SCM
REGN icon

SCS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SCS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$364K Buy
471
+1
+0.2% +$766 ﹤0.01% 386
2025
Q4 		$363K Sell
470
-2
-0.4% -$1.36K ﹤0.01% 406
2025
Q3 		$265K Buy
+472
New +$267K ﹤0.01% 466

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SCS Capital Management's REGN Position: Q1 2026 in Review

SCS Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.21% in Q1 2026, buying an estimated $766 and bringing the position to 471 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #386.

SCS Capital Management first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • SCS Capital Management held 471 shares of Regeneron Pharmaceuticals worth $364K as of Q1 2026.
  • SCS Capital Management bought 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $766.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SCS Capital Management's portfolio in Q1 2026, its #386 holding.
  • SCS Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.